2. Search Result
Search Result
Results for "

LPA1

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

1

Fluorescent Dye

4

Biochemical Assay Reagents

1

Natural
Products

1

Isotope-Labeled Compounds

1

Antibodies

5

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139853
    BMS-986278
    1 Publications Verification

    AdmiLPArant

    		 LPL Receptor Others
    BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases [1].
    BMS-986278
  • HY-137862
    1-Oleoyl lysophosphatidic acid
    3 Publications Verification

    1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA

    		 LPL Receptor Neurological Disease
    1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the LPA receptors. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA receptor activation [1]. 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .
    1-Oleoyl lysophosphatidic acid
  • HY-13285
    Ki16425
    10+ Cited Publications

    Debio 0719

    		 LPL Receptor YAP Neurological Disease Cancer
    Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK [1] . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .
    Ki16425
  • HY-100619
    BMS-986020
    5+ Cited Publications

    AM152

    		 LPL Receptor Metabolic Disease Inflammation/Immunology
    BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist [1]. BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020
  • HY-16040
    AM095 free acid
    10+ Cited Publications

    		 LPL Receptor Inflammation/Immunology
    AM095 (free acid) is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.
    AM095 free acid
  • HY-15277
    AM966
    Maximum Cited Publications
    20 Publications Verification

    		 LPL Receptor Inflammation/Immunology
    AM966 is a high affinity, selective, oral LPA1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC50=17 nM).
    AM966
  • HY-16039
    AM095
    10+ Cited Publications

    		 LPL Receptor Inflammation/Immunology
    AM095 is a selective LPA1 receptor antagonist. The IC50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells is 0.025 and 0.023 μM, respectively.
    AM095
  • HY-18076
    LPA1 receptor antagonist 1

    		LPL Receptor Infection Inflammation/Immunology
    LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 (LPA1) antagonist with an IC50 of 25 nM.
    LPA1 receptor antagonist 1
  • HY-114379
    AS2717638
    2 Publications Verification

    		 LPL Receptor Neurological Disease Inflammation/Immunology
    AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC50 value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases [1] .
    AS2717638
  • HY-100882
    ONO-7300243

    		LPL Receptor Cardiovascular Disease
    ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.
    ONO-7300243
  • HY-150204
    ONO-0740556

    		LPL Receptor Others
    ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC50 value of 0.26 nM [1].
    ONO-0740556
  • HY-138453
    ACT-1016-0707

    LPA1 receptor antagonist 2

    		 LPL Receptor Inflammation/Immunology
    ACT-1016-0707 (Compound 49) is an orally active and selective LPA1 receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases [1].
    ACT-1016-0707
  • HY-117959
    TAK-615

    		LPL Receptor Inflammation/Immunology
    TAK-615 is a negative allosteric modulator (NAM) of the LPA1 receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (Kd high affinity of 1.7 nM and Kd low affinity of 14.5 nM) [1].
    TAK-615
  • HY-100619A
    BMS-986020 sodium
    5+ Cited Publications

    AM152 sodium

    		 LPL Receptor Metabolic Disease Inflammation/Immunology
    BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist [1]. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020 sodium
  • HY-117444
    ONO-9780307

    		LPL Receptor Cancer
    ONO-9780307 is a specific synthetic LPA1 (lysophosphatidic acid receptor 1) antagonist with an IC50 value of 2.7 nM [1].
    ONO-9780307
  • HY-15706
    H2L 5765834
    1 Publications Verification

    		 LPL Receptor Cardiovascular Disease
    H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA1, LPA3, and LPA5, with IC50s of 94, 752, and 463 nM respectively [1].
    H2L 5765834
  • HY-115450
    ONO-0300302

    		LPL Receptor Endocrinology Cancer
    ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC50 of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with Kd of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research [1].
    ONO-0300302
  • HY-120478
    ASP6432

    		LPL Receptor Infection
    ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC50s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively [1].
    ASP6432
  • HY-18641
    Ki16198

    		LPL Receptor Cancer
    Ki16198 is a potent and orally active LPA receptor antagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA1 and LPA3-induced inositol phosphate production with?Ki?values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo [1].
    Ki16198
  • HY-167862A
    UCM-05194 ammonium

    		LPL Receptor Neurological Disease
    UCM-05194 (ammonium) is a lysophosphatidic acid receptor 1 (LPA1) agonist. UCM-05194 (ammonium) induces calcium mobilization in LPA1-expressing RH7777 cells (EC50 = 0.24 µM). UCM-05194 (ammonium) induces neurite retraction and migration in LPA1-overexpressing B103 rat neuroblastoma cells. UCM-05194 (ammonium) attenuates acetic acid-induced writhing and hind paw mechanical hypersensitivity in mice [1].
    UCM-05194 ammonium
  • HY-124072
    HL001

    		Cyclophilin LPL Receptor MDM-2/p53 Apoptosis Reactive Oxygen Species (ROS) Cancer
    HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis [1] .
    HL001
  • HY-167862
    UCM-05194

    		Endogenous Metabolite Neurological Disease
    UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases [1].
    UCM-05194
  • HY-N15794
    AzoLPA ammonium

    		LPL Receptor Neurological Disease
    AzoLPA ammonium is a photoswitchable lipid that activates the Lysophosphatidic acid 1-5 (LPA1-5) receptors’ signaling [1].
    AzoLPA ammonium
  • HY-171806
    BMT-136088

    		LPL Receptor Cancer
    BMT-136088 is a LPAR1 antagonist [1]. 11C-BMT-136088 can be used as a positron emission tomography (PET) radioligand to quantify specific binding to LPA1 in lung.
    BMT-136088
  • HY-182787
    LPA1 receptor antagonist-7

    		LPL Receptor Cancer
    LPA1 receptor antagonist-7 is a LPA1 antagonist. LPA1 receptor antagonist-7 blocks downstream signaling pathways mediated by LPA1. LPA1 receptor antagonist-7 inhibits LPA-induced migration and invasion of cancer cells. LPA1 receptor antagonist-7 can be used for the research of triple-negative breast cancer [1].
    LPA1 receptor antagonist-7
  • HY-W127502
    1-Hexadecyl lysophosphatidic acid

    1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0

    		 Biochemical Assay Reagents Others
    1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.
    1-Hexadecyl lysophosphatidic acid
  • HY-W040176
    N-PTyrosine PA ammonium

    N-Palmitoyl-tyrosine phosphoric acid ammonium

    		 LPL Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    N-PTyrosine PA (N-Palmitoyl-tyrosine phosphoric acid) ammonium is a lysophosphatidic acid (LPA) receptor modulator, which exhibits weak inhibitory activity against LPA1 and partial agonist properties towards LPA5. N-PTyrosine PA ammonium inhibits the activation of LPA receptors and downstream responses by competing with agonists for binding sites. N-PTyrosine PA ammonium can induce morphological changes and aggregation, and also inhibit LPA-induced morphological changes through receptor desensitization caused by pre-incubation. N-PTyrosine PA ammonium can be used in the research of related diseases such as atherosclerosis and acute ischemic syndromes (e.g., unstable angina, myocardial infarction, stroke) [1] .
    N-PTyrosine PA ammonium
  • HY-107614G
    1-Oleoyl lysophosphatidic acid sodium

    1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

    		 LPL Receptor ROCK TGF-beta/Smad TGF-β Receptor Neurological Disease Cancer
    1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer [1] .
    1-Oleoyl lysophosphatidic acid sodium
  • HY-150614
    Autotaxin-IN-6

    		Phosphodiesterase (PDE) LPL Receptor Cancer
    Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC50 value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer [1].
    Autotaxin-IN-6
  • HY-148291
    BrP-LPA sodium

    		LPL Receptor Phosphodiesterase (PDE) Cancer
    BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer [1].
    BrP-LPA sodium
  • HY-129808
    VPC12249

    		LPL Receptor Cardiovascular Disease Cancer
    VPC12249 is a competitive dual LPA1/LPA3 antagonist with Ki values of 137nM and 428 nM, respectively. VPC12249 inhibits calcium mobilization in HEK293T cells with a Ki value of ~130 nM. VPC12249 is promising for research of ovarian cancer and hypertensive diseases [1].
    VPC12249
  • HY-119013
    VPC32183

    		Endogenous Metabolite Cardiovascular Disease
    VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. The activity of VPC32183 can inhibit lipid phosphatase 1 (LPP1), thereby preventing the activation of ERK(1/2) by dioctanoic acid diglyceride (DGPP 8:0). By reducing the expression of LPP1, VPC32183 can further reduce DGPP 8:0-induced ERK(1/2) activation. The effects of VPC32183 suggest that it may have a positive regulatory function in cell signaling processes [1].
    VPC32183
  • HY-13285R
    Ki16425 (Standard)

    Debio 0719 (Standard)

    		 LPL Receptor YAP Reference Standards Neurological Disease Cancer
    Ki16425 (Standard) is the analytical standard of Ki16425. This product is intended for research and analytical applications. Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK [1] . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .
    Ki16425 (Standard)
  • HY-178845
    Decyl phosphate

    Decyl dihydrogen phosphate

    		 LPL Receptor Cardiovascular Disease
    Decyl phosphate is a selective LPA2 agonist (EC50: 1.8 μM) and LPA1/LPA3 antagonist. Decyl phosphate can be used in the research of blood disorders [1].
    Decyl phosphate
  • HY-W923661
    1-Octadecyl lysophosphatidic acid

    PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA

    		 LPL Receptor Others
    1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects [1].
    1-Octadecyl lysophosphatidic acid
  • HY-RS28933
    Bud31 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Bud31 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bud31 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Bud31 Rat Pre-designed siRNA Set A
    Bud31 Rat Pre-designed siRNA Set A
  • HY-RS07747
    Lpar1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Lpar1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lpar1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Lpar1 Mouse Pre-designed siRNA Set A
    Lpar1 Mouse Pre-designed siRNA Set A
  • HY-100882R
    ONO-7300243 (Standard)

    		LPL Receptor Reference Standards Cardiovascular Disease
    ONO-7300243 (Standard) is the analytical standard of ONO-7300243 (HY-100882). This product is intended for research and analytical applications. ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.
    ONO-7300243 (Standard)
  • HY-RS07746
    LPAR1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    LPAR1 Human Pre-designed siRNA Set A contains three designed siRNAs for LPAR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LPAR1 Human Pre-designed siRNA Set A
    LPAR1 Human Pre-designed siRNA Set A
  • HY-157617
    16:0 Cyclic LPA ammonium

    1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate ammonium

    		 Biochemical Assay Reagents Others
    16:0 Cyclic LPA (1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate) ammonium is a palmitoyl cyclic phosphatidic acid [1].
    16:0 Cyclic LPA ammonium
  • HY-W725737
    BrP-LPA

    		LPL Receptor Phosphodiesterase (PDE) Neurological Disease Cancer
    BrP-LPA is a LPA antagonist/ATX inhibitor. BrP-LPA shows pan-antagonist activity towards LPA1-4 GPCRs. BrP-LPA decreases blood vessel density. BrP-LPA dose-dependently inhibits Lysophosphatidic acid-induced head-dip counts. BrP-LPA exhibits anticancer activity against breast cancer, colon cancer, and lung cancer. BrP-LPA inhibits anxiety-like behavior [1] .
    BrP-LPA
  • HY-100619AR
    BMS-986020 sodium (Standard)

    AM152 sodium (Standard)

    		 LPL Receptor Reference Standards Metabolic Disease Inflammation/Immunology
    BMS-986020 (sodium) (Standard) is the analytical standard of BMS-986020 (sodium) (HY-100619A). This product is intended for research and analytical applications. BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist [1]. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020 sodium (Standard)
  • HY-100619R
    BMS-986020 (Standard)

    AM152 (Standard)

    		 LPL Receptor Reference Standards Metabolic Disease Inflammation/Immunology
    BMS-986020 (Standard) is the analytical standard of BMS-986020 (HY-100619). This product is intended for research and analytical applications. BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist [1]. BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020 (Standard)
  • HY-172566
    1-Myristyl-2-hydroxy-sn-glycero-3-PA

    1-Myristyl LPA

    		 Drug Derivative Calcium Channel Others
    1-Myristyl-2-hydroxy-sn-glycero-3-PA (1-Myristyl LPA) is a lysophosphatidic acid derivative. 1-Myristyl-2-hydroxy-sn-glycero-3-PA can increase intracellular calcium concentration in HEL cells [1].
    1-Myristyl-2-hydroxy-sn-glycero-3-PA
  • HY-157669
    1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium

    18:1 Cyclic LPA

    		 Biochemical Assay Reagents Others
    1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic phosphatidic acid that can be used for the preparation of liposomes [1].
    1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium
  • HY-126967AS
    1-Palmitoyl-sn-glycerol 3-phosphate-d9

    1-P-GPA-d9

    		 Isotope-Labeled Compounds Metabolic Disease
    1-Palmitoyl-sn-glycerol 3-phosphate-d9 is the deuterium labeled 1-Palmitoyl-sn-glycerol 3-phosphate (1-Palmitoyl LPA). 1-Palmitoyl LPA is an analog of LPA that contains palmitic acid at the sn-1 position.
    1-Palmitoyl-sn-glycerol 3-phosphate-d9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: